Clinical Trial: Alemtuzumab and Rituximab in Aplastic Anemia

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia

Brief Summary: The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.

Detailed Summary:
Sponsor: Hospital Universitario Dr. Jose E. Gonzalez

Current Primary Outcome: Evaluate efficacy of alemtuzumab and rituximab in aplastic anemia. [ Time Frame: 12 months ]

Evaluate the hematological response after the administration of alemtuzumab and rituximab


Original Primary Outcome: Same as current

Current Secondary Outcome: Measuring the side effects of alemtuzumab and rituximab combination through clinical evaluation [ Time Frame: 12 months ]

Original Secondary Outcome: Same as current

Information By: Hospital Universitario Dr. Jose E. Gonzalez

Dates:
Date Received: July 29, 2011
Date Started: July 2011
Date Completion:
Last Updated: January 3, 2014
Last Verified: January 2014